Get Alert
Please Wait... Processing your request... Please Wait.
You must sign in to sign-up for alerts.

Please confirm that your email address is correct, so you can successfully receive this alert.

Articles   |    
The Risk of Switch to Mania in Patients With Bipolar Disorder During Treatment With an Antidepressant Alone and in Combination With a Mood Stabilizer
Alexander Viktorin, M.Sc.; Paul Lichtenstein, Ph.D.; Michael E. Thase, M.D.; Henrik Larsson, Ph.D.; Cecilia Lundholm, M.Sc.; Patrik K.E. Magnusson, Ph.D.; Mikael Landén, M.D., Ph.D.
Am J Psychiatry 2014;171:1067-1073. doi:10.1176/appi.ajp.2014.13111501
View Author and Article Information

Dr. Thase has served as a consultant for Alkermes, AstraZeneca, Bristol-Myers Squibb, Cerecor, Eli Lilly, Dey Pharma, Forest Laboratories (including PGx), Gerson Lehman Group, Guidepoint Global, Lundbeck, MedAvante, Merck (including Schering-Plough and Organon), Neuronetics, Ortho-McNeil (including Johnson & Johnson), Otsuka, Pamlab, Pfizer (including Wyeth-Ayerst Pharmaceuticals), PGx, Shire, Sunovion, Supernus, Takeda, and Transcept Pharmaceuticals; he has received grant support from the Agency for Healthcare Research and Quality, Alkermes, Eli Lilly, Forest Pharmaceuticals, NIMH, Otsuka, PharmaNeuroboost, and Roche; he has equity holdings in MedAvante and has received royalties from the American Psychiatric Foundation, Guilford Press, Herald House, and W.W. Norton; his spouse is employed by Peloton Advantage (Formerly Advogent and Embryon), which does business with Pfizer/Wyeth. Dr. Landén has received lecture honoraria from AstraZeneca, Bayer, Biophausia, Bristol-Myers Squibb, and Servier Sweden and has served on an advisory board for Lundbeck. The other authors report no financial relationships with commercial interests.

Supported by grants from the Swedish Medical Research Council (K2014-62X-14647-12-51 and K2010-61P-21568-01-4), the Swedish Foundation for Strategic Research, and the Swedish Brain Foundation.

From the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm; the Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden; and the Department of Psychiatry, University of Pennsylvania, Philadelphia.

Address correspondence to Dr. Landén (mikael.landen@neuro.gu.se).

Copyright © 2014 by the American Psychiatric Association

Received November 15, 2013; Revised March 27, 2014; Accepted April 25, 2014.


Objective  This study examined the risk of antidepressant-induced manic switch in patients with bipolar disorder treated either with antidepressant monotherapy or with an antidepressant in conjunction with a mood stabilizer.

Method  Using Swedish national registries, the authors identified 3,240 patients with bipolar disorder who started treatment with an antidepressant and had no antidepressant treatment during the previous year. Patients were categorized into those receiving antidepressant monotherapy and those receiving an antidepressant plus a mood stabilizer. A within-individual design was used to control for confounding by disorder severity, genetic makeup, and early environmental factors. Cox regression analyses conditioned on individual were used to compare the rate of mania 0–3 months and 3–9 months after the start of antidepressant treatment with a preceding non-treatment period.

Results  Nearly 35% of the patients were treated with antidepressant monotherapy. The increased risk of treatment-emergent mania was confined to patients on antidepressant monotherapy (hazard ratio=2.83, 95% CI=1.12, 7.19). Among patients treated with a concurrent mood stabilizer, no acute change in risk of mania was observed during the 3 months after the start of antidepressant treatment (hazard ratio=0.79, 95% CI=0.54, 1.15), and a decreased risk was observed during the period 3–9 months after treatment initiation (hazard ratio=0.63, 95% CI=0.42, 0.93).

Conclusions  In this national registry study, antidepressant monotherapy was associated with an increased risk of mania. However, no risk of mania was seen in patients receiving an antidepressant while treated with a mood stabilizer. The results highlight the importance of avoiding antidepressant monotherapy in the treatment of bipolar disorder.

Abstract Teaser
Figures in this Article

Your Session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

FIGURE 1. Description of the Within-Individual Design of a National Registry Study of Patients With Bipolar Disordera

a The design allows for comparisons of mania after initiation of antidepressant treatment with a preceding non-treatment period within each subject. The follow-up time was split into 0–3 months and 3–9 months to assess acute (switch) effects and longer-term effects. By applying a within-individual design, confounding by differences in disorder severity, genetic makeup, and early environmental factors is reduced.

Anchor for Jump
TABLE 1.Baseline Characteristics of Patients With Bipolar Disorder in a National Registry Study (N=3,240)
Anchor for Jump
TABLE 2.Specific Antidepressants Dispensed to Patients With Bipolar Disorder in a National Registry Studya
Table Footer Note

a The antidepressants and numbers listed here are those that were dispensed at the start of the treatment period. Because we applied strict inclusion criteria to classify patients as being on a concurrent mood stabilizer or not, 482 patients from the full sample with ambiguous mood stabilizer use were not classified as either receiving monotherapy or receiving concurrent mood stabilizer treatment. Therefore, the sum of the individuals in the antidepressant monotherapy group and mood stabilizer group do not add up to the full sample.

Anchor for Jump
TABLE 3.Mania Diagnoses Before and After Antidepressant Treatment Among Patients With Bipolar Disorder Treated With an Antidepressant in a National Registry Study (N=3,240)a
Table Footer Note

a Mania rate is computed as the number of mania diagnoses divided by number of patients. The hazard ratio for mania during an acute and a longer-term period after antidepressant treatment is based on comparison with a prior non-treatment period.

Anchor for Jump
TABLE 4.Mania Diagnoses Among Patients With Bipolar Disorder in a National Registry Study Who Received Antidepressant Monotherapy or an Antidepressant and a Concurrent Mood Stabilizera
Table Footer Note

a Mania rate is computed as the number of mania diagnoses divided by number of patients. The hazard ratio for mania during an acute and a longer-term period after antidepressant treatment is based on comparison with a prior non-treatment period. Because we applied strict inclusion criteria to classify patients as being on a concurrent mood stabilizer or not, 482 patients with ambiguous mood stabilizer use were excluded from the subsequent analyses.



Thase  ME:  Bipolar depression: diagnostic and treatment considerations.  Dev Psychopathol 2006; 18:1213–1230
[CrossRef] | [PubMed]
Judd  LL;  Akiskal  HS;  Schettler  PJ;  Coryell  W;  Endicott  J;  Maser  JD;  Solomon  DA;  Leon  AC;  Keller  MB:  A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder.  Arch Gen Psychiatry 2003; 60:261–269
[CrossRef] | [PubMed]
Judd  LL;  Akiskal  HS;  Schettler  PJ;  Endicott  J;  Maser  J;  Solomon  DA;  Leon  AC;  Rice  JA;  Keller  MB:  The long-term natural history of the weekly symptomatic status of bipolar I disorder.  Arch Gen Psychiatry 2002; 59:530–537
[CrossRef] | [PubMed]
Kupka  RW;  Altshuler  LL;  Nolen  WA;  Suppes  T;  Luckenbaugh  DA;  Leverich  GS;  Frye  MA;  Keck  PE  Jr;  McElroy  SL;  Grunze  H;  Post  RM:  Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder.  Bipolar Disord 2007; 9:531–535
[CrossRef] | [PubMed]
López  P;  Mosquera  F;  de León  J;  Gutiérrez  M;  Ezcurra  J;  Ramírez  F;  González-Pinto  A:  Suicide attempts in bipolar patients.  J Clin Psychiatry 2001; 62:963–966
[CrossRef] | [PubMed]
Judd  LL;  Akiskal  HS;  Schettler  PJ;  Endicott  J;  Leon  AC;  Solomon  DA;  Coryell  W;  Maser  JD;  Keller  MB:  Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study.  Arch Gen Psychiatry 2005; 62:1322–1330
[CrossRef] | [PubMed]
Baldessarini  RJ;  Leahy  L;  Arcona  S;  Gause  D;  Zhang  W;  Hennen  J:  Patterns of psychotropic drug prescription for US patients with diagnoses of bipolar disorders.  Psychiatr Serv 2007; 58:85–91
[CrossRef] | [PubMed]
Geddes  JR;  Carney  SM;  Davies  C;  Furukawa  TA;  Kupfer  DJ;  Frank  E;  Goodwin  GM:  Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review.  Lancet 2003; 361:653–661
[CrossRef] | [PubMed]
Maj  M;  Pirozzi  R;  Magliano  L;  Bartoli  L:  The prognostic significance of “switching” in patients with bipolar disorder: a 10-year prospective follow-up study.  Am J Psychiatry 2002; 159:1711–1717
[CrossRef] | [PubMed]
Wehr  TA;  Goodwin  FK:  Rapid cycling in manic-depressives induced by tricyclic antidepressants.  Arch Gen Psychiatry 1979; 36:555–559
[CrossRef] | [PubMed]
Ball  JR;  Kiloh  LG:  A controlled trial of imipramine in treatment of depressive states.  BMJ 1959; 2:1052–1055
[CrossRef] | [PubMed]
Leyberg  JT;  Denmark  JC:  The treatment of depressive states with imipramine hydrochloride (Tofranil).  J Ment Sci 1959; 105:1123–1126
Altshuler  LL;  Post  RM;  Leverich  GS;  Mikalauskas  K;  Rosoff  A;  Ackerman  L:  Antidepressant-induced mania and cycle acceleration: a controversy revisited.  Am J Psychiatry 1995; 152:1130–1138
Boerlin  HL;  Gitlin  MJ;  Zoellner  LA;  Hammen  CL:  Bipolar depression and antidepressant-induced mania: a naturalistic study.  J Clin Psychiatry 1998; 59:374–379
[CrossRef] | [PubMed]
Peet  M:  Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants.  Br J Psychiatry 1994; 164:549–550
[CrossRef] | [PubMed]
Prien  RF;  Klett  CJ;  Caffey  EM  Jr:  Lithium carbonate and imipramine in prevention of affective episodes: a comparison in recurrent affective illness.  Arch Gen Psychiatry 1973; 29:420–425
[CrossRef] | [PubMed]
Truman  CJ;  Goldberg  JF;  Ghaemi  SN;  Baldassano  CF;  Wisniewski  SR;  Dennehy  EB;  Thase  ME;  Sachs  GS:  Self-reported history of manic/hypomanic switch associated with antidepressant use: data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).  J Clin Psychiatry 2007; 68:1472–1479
[CrossRef] | [PubMed]
Valentí  M;  Pacchiarotti  I;  Bonnín  CM;  Rosa  AR;  Popovic  D;  Nivoli  AM;  Goikolea  JM;  Murru  A;  Undurraga  J;  Colom  F;  Vieta  E:  Risk factors for antidepressant-related switch to mania.  J Clin Psychiatry 2012; 73:e271–e276
[CrossRef] | [PubMed]
Angst  J:  Switch from depression to mania: a record study over decades between 1920 and 1982.  Psychopathology 1985; 18:140–154
[CrossRef] | [PubMed]
Lewis  JL;  Winokur  G:  The induction of mania: a natural history study with controls.  Arch Gen Psychiatry 1982; 39:303–306
[CrossRef] | [PubMed]
Visser  HM;  Van Der Mast  RC:  Bipolar disorder, antidepressants, and induction of hypomania or mania: a systematic review.  World J Biol Psychiatry 2005; 6:231–241
[CrossRef] | [PubMed]
Nivoli  AM;  Colom  F;  Murru  A;  Pacchiarotti  I;  Castro-Loli  P;  González-Pinto  A;  Fountoulakis  KN;  Vieta  E:  New treatment guidelines for acute bipolar depression: a systematic review.  J Affect Disord 2011; 129:14–26
[CrossRef] | [PubMed]
Bottlender  R;  Rudolf  D;  Strauss  A;  Möller  HJ:  Mood-stabilisers reduce the risk of developing antidepressant-induced maniform states in acute treatment of bipolar I depressed patients.  J Affect Disord 2001; 63:79–83
[CrossRef] | [PubMed]
Henry  C;  Sorbara  F;  Lacoste  J;  Gindre  C;  Leboyer  M:  Antidepressant-induced mania in bipolar patients: identification of risk factors.  J Clin Psychiatry 2001; 62:249–255
[CrossRef] | [PubMed]
Leverich  GS;  Altshuler  LL;  Frye  MA;  Suppes  T;  McElroy  SL;  Keck  PE  Jr;  Kupka  RW;  Denicoff  KD;  Nolen  WA;  Grunze  H;  Martinez  MI;  Post  RM:  Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers.  Am J Psychiatry 2006; 163:232–239
[CrossRef] | [PubMed]
Young  LT;  Joffe  RT;  Robb  JC;  MacQueen  GM;  Marriott  M;  Patelis-Siotis  I:  Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression.  Am J Psychiatry 2000; 157:124–126
[CrossRef] | [PubMed]
Tondo  L;  Vázquez  G;  Baldessarini  RJ:  Mania associated with antidepressant treatment: comprehensive meta-analytic review.  Acta Psychiatr Scand 2010; 121:404–414
[CrossRef] | [PubMed]
Ludvigsson  JF;  Otterblad-Olausson  P;  Pettersson  BU;  Ekbom  A:  The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research.  Eur J Epidemiol 2009; 24:659–667
[CrossRef] | [PubMed]
Ludvigsson  JF;  Andersson  E;  Ekbom  A;  Feychting  M;  Kim  JL;  Reuterwall  C;  Heurgren  M;  Olausson  PO:  External review and validation of the Swedish national inpatient register.  BMC Public Health 2011; 11:450
[CrossRef] | [PubMed]
Sellgren  C;  Landén  M;  Lichtenstein  P;  Hultman  CM;  Långström  N:  Validity of bipolar disorder hospital discharge diagnoses: file review and multiple register linkage in Sweden.  Acta Psychiatr Scand 2011; 124:447–453
[CrossRef] | [PubMed]
Wettermark  B;  Hammar  N;  Fored  CM;  Leimanis  A;  Otterblad Olausson  P;  Bergman  U;  Persson  I;  Sundström  A;  Westerholm  B;  Rosén  M:  The new Swedish Prescribed Drug Register: opportunities for pharmacoepidemiological research and experience from the first six months.  Pharmacoepidemiol Drug Saf 2007; 16:726–735
[CrossRef] | [PubMed]
Goldberg  JF;  Truman  CJ:  Antidepressant-induced mania: an overview of current controversies.  Bipolar Disord 2003; 5:407–420
[CrossRef] | [PubMed]
Pacchiarotti  I;  Bond  DJ;  Baldessarini  RJ;  Nolen  WA;  Grunze  H;  Licht  RW;  Post  RM;  Berk  M;  Goodwin  GM;  Sachs  GS;  Tondo  L;  Findling  RL;  Youngstrom  EA;  Tohen  M;  Undurraga  J;  González-Pinto  A;  Goldberg  JF;  Yildiz  A;  Altshuler  LL;  Calabrese  JR;  Mitchell  PB;  Thase  ME;  Koukopoulos  A;  Colom  F;  Frye  MA;  Malhi  GS;  Fountoulakis  KN;  Vázquez  G;  Perlis  RH;  Ketter  TA;  Cassidy  F;  Akiskal  H;  Azorin  JM;  Valentí  M;  Mazzei  DH;  Lafer  B;  Kato  T;  Mazzarini  L;  Martínez-Aran  A;  Parker  G;  Souery  D;  Ozerdem  A;  McElroy  SL;  Girardi  P;  Bauer  M;  Yatham  LN;  Zarate  CA;  Nierenberg  AA;  Birmaher  B;  Kanba  S;  El-Mallakh  RS;  Serretti  A;  Rihmer  Z;  Young  AH;  Kotzalidis  GD;  MacQueen  GM;  Bowden  CL;  Ghaemi  SN;  Lopez-Jaramillo  C;  Rybakowski  J;  Ha  K;  Perugi  G;  Kasper  S;  Amsterdam  JD;  Hirschfeld  RM;  Kapczinski  F;  Vieta  E:  The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders.  Am J Psychiatry 2013; 170:1249–1262
[CrossRef] | [PubMed]
References Container

Self-Assessment Quiz

Did you know? You can add a subscription now to earn CME Credits!

A major hurdle in pharmacoepidemiological studies is confounding by indication, which is best described by which of the following?
What is the most likely outcome of comparing the incidence of manic episodes in patients treated with antidepressant monotherapy or in combination with a mood stabilizer?
One concern regarding antidepressant use in bipolar disorder is that they might induce a switch from depression to mania. In what group of antidepressants was this observation first noted?
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of APA editorial staff.

* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe

Related Content
DSM-5™ Clinical Cases > Chapter 3.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 2.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 5.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 1.  >
The American Psychiatric Publishing Textbook of Psychiatry, 5th Edition > Chapter 26.  >
Topic Collections
Psychiatric News
APA Guidelines
PubMed Articles